An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

PHASE3RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

September 17, 2026

Study Completion Date

September 17, 2027

Conditions
Type 1 DiabetesKidney Transplant
Interventions
BIOLOGICAL

Biological/Vaccine

Infused into the hepatic portal vein.

Trial Locations (7)

15213

RECRUITING

Montefiore Clinical and Translational Research Center - Endocrinology, Pittsburgh

19104

RECRUITING

Perelman Center for Advanced Medicine - Endocrinology, Philadelphia

53792

RECRUITING

UW University Hospital - Endocrinology, Madison

Unknown

RECRUITING

Toronto General Hospital - Endocrinology, Toronto

RECRUITING

Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre, Vancouver

RECRUITING

King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology, Riyadh

RECRUITING

King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology, Riyadh

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY